0001209191-23-001342.txt : 20230104 0001209191-23-001342.hdr.sgml : 20230104 20230104182448 ACCESSION NUMBER: 0001209191-23-001342 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221230 FILED AS OF DATE: 20230104 DATE AS OF CHANGE: 20230104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mancini Marianna CENTRAL INDEX KEY: 0001838112 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37355 FILM NUMBER: 23508820 MAIL ADDRESS: STREET 1: C/O VIKING THERAPEUTICS, INC. STREET 2: 12340 EL CAMINO REAL, STE 250 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Viking Therapeutics, Inc. CENTRAL INDEX KEY: 0001607678 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 461073877 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-704-4660 MAIL ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-12-30 0 0001607678 Viking Therapeutics, Inc. VKTX 0001838112 Mancini Marianna C/O VIKING THERAPEUTICS, INC. 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 0 1 0 0 Chief Operating Officer Common Stock, par value $0.00001 per share 2022-12-30 4 A 0 23500 0.00 A 273306 D Common Stock, par value $0.00001 per share 2022-12-30 4 F 0 12773 9.40 D 260533 D Common Stock, par value $0.00001 per share 2023-01-03 4 A 0 90667 0.00 A 351200 D Common Stock, par value $0.00001 per share 2023-01-03 4 F 0 18854 8.52 D 332346 D Common Stock, par value $0.00001 per share 2023-01-04 4 F 0 13994 8.42 D 318352 D Stock Option (Right to Buy) 8.52 2023-01-03 4 A 0 204000 0.00 A 2024-01-03 2033-01-03 Common Stock 204000 204000 D The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2019, 66.67% of which vested on December 30, 2022 upon the achievement of two non-financial performance goals and a performance restricted stock unit award that was granted on January 4, 2021, 33.33% of which vested on December 30, 2022 upon the achievement of a non-financial performance goal. Includes 4,545 shares acquired on May 20, 2022 and 6,566 shares acquired on November 18, 2022 pursuant to the Issuer's 2014 Employee Stock Purchase Plan These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units. Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units. 25% of the shares subject to the option will vest on each anniversary of the grant date. /s/ Michael Morneau, as Attorney-in-Fact 2023-01-04